This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Here's Why Centene (CNC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Industry Stocks to Watch as Technology Expenses Take a Toll
by Debasmita Chatterjee
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Centene (CNC) Down 3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner
by Zacks Equity Research
PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner are part of the Zacks top Analyst Blog.
Top Analyst Reports for PepsiCo, Salesforce & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Salesforce, Inc. (CRM) and Advanced Micro Devices, Inc. (AMD).
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
by Zacks Equity Research
Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
by Zacks Equity Research
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
Teladoc Health (TDOC) Shares Up 5% Since Q1 Earnings Release
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results reflect solid chronic care product revenues and improving access fees and other revenues.
Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
Universal Health (UHS) Q1 Earnings Beat on Higher Admissions
by Zacks Equity Research
Universal Health's (UHS) Q1 results reflect strong performance in acute care and behavioral health segments. Meanwhile, the elevated expense level partially offsets the positives.
Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums
by Zacks Equity Research
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
by Zacks Equity Research
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
Centene (CNC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Centene (CNC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Centene (CNC) Misses Q1 Earnings Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -5.38% and 7.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Should Vanguard Mid-Cap Value ETF (VOE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOE
Why Centene (CNC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene (CNC) Expands Evolent Partnership to Boost Quality
by Zacks Equity Research
Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Stocks to Watch Despite Elevated Tech Costs, Nursing Shortage
by Debasmita Chatterjee
Improved premiums cropping from a solid customer base might aid the Medical-HMO industry. However, an escalating expense level and an acute shortage of nurses are roadblocks. Stocks like UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Should Vanguard Mid-Cap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO